SCHEMBL2277217

SCHEMBL2277217

CC(=O)c1cccc(OC(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.54
MEN1 O00255 4/20 0.54
RAB9A P51151 4/20 0.54
NPSR1 Q6W5P4 3/20 0.54
MAPT P10636 3/20 0.54
LMNA P02545 2/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
MAOB P27338 7/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
POLB P06746 1/20 0.52
HTT P42858 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
NPC1 O15118 3/20 0.52
ATM Q13315 1/20 0.51
GAA P10253 1/20 0.51
ALDH1A1 P00352 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MAOA P21397 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16950311 0.87 KMT2A (0.51) KMT2AMEN1RAB9ANPSR1MAPT
SCHEMBL4106010 0.85 MEN1 (0.63) KMT2AMEN1RAB9ANPSR1MAPT
SCHEMBL1965898 0.83 MRGPRX4 (0.63) KMT2AMEN1RAB9ANPSR1MAPT
SCHEMBL30744738 0.83 MRGPRX4 (0.63) KMT2AMEN1RAB9ANPSR1MAPT
SCHEMBL104194 0.83 KMT2A (0.59) KMT2AMEN1RAB9ALMNAMAOB
SCHEMBL1619240 0.83 MAPT (0.52) KMT2AMEN1RAB9AMAPTLMNA
SCHEMBL756320 0.82 KMT2A (0.51) KMT2AMEN1RAB9ANPSR1MAPT
SCHEMBL30744976 0.82 LMNA (0.56) KMT2AMEN1RAB9ANPSR1MAPT
SCHEMBL1854891 0.82 LMNA (0.56) KMT2AMEN1RAB9ANPSR1MAPT
SCHEMBL9567403 0.81 KMT2A (0.57) KMT2AMEN1RAB9ANPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115697980-B Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2025-03-21 CN disclosed
EP-4139286-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 EP disclosed
CN-118994142-A Furanamide compound and application thereof 浙江大学金华研究院 2024-11-22 CN disclosed
US-20240376091-A1 THIADIAZOLEAMIDE DERIVATIVES AND THEIR APPLICATIONS ZHEJIANG UNIVERSITY (CN) 2024-11-14 US disclosed
EP-4461725-A2 ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS H. Lundbeck A/S (DK) 2024-11-13 EP disclosed
CN-114206830-B Alcohol derivatives as Kv7 potassium channel openers H.隆德贝克有限公司 2024-07-30 CN disclosed
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-04-23 US disclosed
US-11760701-B2 Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YROK (US) 2023-09-19 US disclosed
US-11760701-B2 Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YROK (US) 2023-09-19 US disclosed
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-7105670-B2 Intermediates useful in the preparation of diaminothiazoles HOFFMANN-LA ROCHE INC. (US) 2006-09-12 US disclosed
US-7094896-B2 Diaminothiazoles having antiproliferative activity HOFFMANN-LA ROCHE INC. (US) 2006-08-22 US disclosed
EP-1358169-B1 DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE HOFFMANN LA ROCHE (CH) 2006-01-11 EP disclosed
US-6756374-B2 CYCLIN-DEPENDENT KINASE INHIBITORS SUCH AS (4-AMINO-2-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-5-THIAZOLYL) (2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)METHANONE FOR TREATMENT OF BREAST, LUNG, COLON, AND PROSTATE CANCER/TUMORS HOFFMANN-LA ROCHE INC. 2004-06-29 US disclosed
US-20040087594-A1 Diaminothiazoles having antiproliferative activity DING QINGJIE (US) 2004-05-06 US disclosed
US-20040082595-A1 Intermediates useful in the preparation of diaminothiazoles DING QINGJIE (US) 2004-04-29 US disclosed
EP-1358169-A2 DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE F. HOFFMANN-LA ROCHE AG (CH) 2003-11-05 EP disclosed
US-20020151554-A1 Diaminothiazoles having antiproliferative activity CHEN LI (US) 2002-10-17 US disclosed
WO-2002057261-A2 DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE F. HOFFMANN-LA ROCHE AG (CH) 2002-07-25 WO disclosed
US-4665074-A CARDIOTONIC, BRONCHOSPASMOLYTIC BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1987-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087594-A1 Diaminothiazoles having antiproliferative activity CDK4, CDK2, CDKL4 KMT2A 634/4885MEN1 2126/4885RAB9A 4189/4885
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG KMT2A 1150/4885MEN1 4344/4885RAB9A 951/4885
US-20020151554-A1 Diaminothiazoles having antiproliferative activity CDK4, CDK2, CDKL4 KMT2A 634/4885MEN1 2126/4885RAB9A 4189/4885
US-20040082595-A1 Intermediates useful in the preparation of diaminothiazoles CDK4, CDK2, CDKL4 KMT2A 751/4885MEN1 1319/4885RAB9A 3806/4885
US-20240376091-A1 THIADIAZOLEAMIDE DERIVATIVES AND THEIR APPLICATIONS AR, GPER1, CYP19A1 KMT2A 1661/4885MEN1 4209/4885RAB9A 3272/4885
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation DGKZ, DGKA, DGKG KMT2A 1150/4885MEN1 4344/4885RAB9A 951/4885
US-11760701-B2 Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same AFF2, AFF4, AFF1 KMT2A 349/4885MEN1 398/4885RAB9A 3109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.